Kelonia Therapeutics Emerges with $50M to Deliver Precision Targeted Genetic Medicines

Kelonia Therapeutics Emerges with $50M to Deliver Precision Targeted Genetic Medicines

Kelonia Therapeutics focused on vivo gene delivery, launched with a $50M in funding to expand the benefit and reach of genetic medicines.

What You Should Know:

Kelonia Therapeutics, a Boston-based biotech company focused on vivo gene delivery, launched with a $50 million in Series A funding to expand the benefit and reach of genetic medicines.

– Despite life-changing responses, existing gene therapies are highly complex, costly, and limited by complicated treatment paradigms, tractable therapeutic applications, and dose-limiting toxicities. By enabling precisely targeted, highly efficient, manufacturable “off-the-shelf” in vivo gene delivery, Kelonia’s technology has the potential to dramatically expand the impact and reach of genetic medicines to every patient in need.




Next Article

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2024 Netspective Media LLC. All Rights Reserved.

Built on May 28, 2024 at 11:33am